US Stock MarketDetailed Quotes

BRNS Barinthus Biotherapeutics

Watchlist
  • 1.110
  • +0.090+8.82%
Close Dec 20 16:00 ET
  • 1.160
  • +0.050+4.50%
Post 20:01 ET
44.65MMarket Cap-0.74P/E (TTM)
Full Hours
  • 5D
  • Daily
  • Weekly
  • Monthly
  • 1Q
  • 1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Comments

    Jaguar8
    Jaguar8
    Nov 15 10:03
    NEWS
    $Barinthus Biotherapeutics (BRNS.US)$
    Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis B
    Arbutus Biopharma and Barinthus Bio announced new preliminary data from Phase 2a IM-PROVE II trial showing enhanced results when combining imdusiran, VTP-300, and low-dose nivolumab in treating chronic hepatitis B virus. 23% of participants receiving this combination achieved HBsAg l...
    Jaguar8
    Jaguar8
    Oct 31 07:22
    NEWS
    $Barinthus Biotherapeutics (BRNS.US)$
    Barinthus Bio Announces Late Breaking Presentation at AASLD 2024 – The Liver Meeting® and Attendance at November Conferences
    Barinthus Biotherapeutics (NASDAQ: BRNS) announced that updated clinical data from its chronic hepatitis B program will be presented at The Liver Meeting® 2024 in San Diego. The late-breaking presentation will focus on VTP-300 combined with low-dose nivolumab and its association with HBsAg loss in specific chronic hepatitis B patien...
    Trytosaveabit
    Trytosaveabit
    Oct 21 18:10
    Watching for upcoming data release!
    $Barinthus Biotherapeutics (BRNS.US)$ •In the fourth quarter of 2024, the Company expects to:
    ◦VTP-300 (HBV):
    ▪Announce updated interim data from HBV003, our Phase 2b trial evaluating additional dosing of VTP-300 and timing of PD-1 inhibition, in people with CHB on NUC therapy.
    ▪Announce updated interim data from the Phase 2a AB-729-202 clinical trial evaluating the combination of VTP-300 and Arbutus’ imdusiran, in people with CHB on NUC therapy.
    Jaguar8
    Jaguar8
    Oct 1 07:07
    NEWS
    $Barinthus Biotherapeutics (BRNS.US)$
    Barinthus Bio Completes Enrollment for Phase 2b HBV003 Clinical Trial in Chronic Hepatitis B and Phase 1 PCA001 Clinical Trial in Prostate Cancer
    • Investigational immunotherapy, VTP-300, is being evaluated as part of a potential functional cure regimen for chronic Hepatitis B.
    • Interim data update for HBV003 anticipated in Q4 2024.
    • Data update for PCA001 anticipated in H1 2025.
    OXFORD, United Kingdom, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Barinthus B...
Read more
Trending US Stocks
Best Growth Stocks Best Growth Stocks

Spot stocks with huge growth potential and solid financial standing. Spot stocks with huge growth potential and solid financial standing.

Symbol Mini Chart % Chg
Ermenegildo Zegna NV
ZGN
+6.16%
DexCom
DXCM
+5.57%
New Fortress Energy
NFE
+5.37%
Workday
WDAY
+2.33%
eBay
EBAY
+1.66%

Unlock the Full List